We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-6.17%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.29B
AUM Growth
-$232M
Cap. Flow
+$49.5M
Cap. Flow %
3.84%
Top 10 Hldgs %
64.8%
Holding
49
New
12
Increased
11
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$19.3M
2
NVTA
Invitae Corporation
NVTA
+$19.3M
3
TSVT
2seventy bio
TSVT
+$17.4M
4
TWST icon
Twist Bioscience
TWST
+$16.8M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$60.4M
2
RLAY icon
Relay Therapeutics
RLAY
+$31.6M
3
VERV
Verve Therapeutics
VERV
+$23.5M
4
EXAS
Exact Sciences
EXAS
+$16.4M
5
BPMC
Blueprint Medicines
BPMC
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$527M
$14M 1.08%
+630,000
New +$9.73M
PRME icon
27
Prime Medicine
PRME
$508M
$13.6M 1.06%
+734,350
New +$13.3M
TNYA icon
28
Tenaya Therapeutics
TNYA
$158M
$12.2M 0.95%
6,078,860
+2,492,042
+69% +$6.08M
MRNA icon
29
Moderna
MRNA
$21.9B
$10.8M 0.84%
60,000
+27,500
+85% +$4.5M
NTLA icon
30
Intellia Therapeutics
NTLA
$1.5B
$10.3M 0.8%
295,000
– –
VEEV icon
31
Veeva Systems
VEEV
$33.5B
$8.07M 0.63%
+50,000
New +$8.54M
ARVN icon
32
Arvinas
ARVN
$520M
$6.84M 0.53%
200,000
– –
INCY icon
33
Incyte
INCY
$24B
$6.22M 0.48%
+77,500
New +$5.93M
MRNA icon
34
CALL
Moderna
MRNA
$21.9B
$5.39M 0.42%
+30,000
New +$4.91M
DICE
35
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$5.15M 0.4%
+165,000
New +$5.38M
MRTX
36
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.53M 0.35%
100,000
– –
OPRX icon
37
OptimizeRx
OPRX
$123M
$4.37M 0.34%
+260,000
New +$4.5M
WGS icon
38
GeneDx Holdings
WGS
$2.01B
$4.34M 0.34%
498,106
– –
DH icon
39
Definitive Healthcare
DH
$73.9M
$3.96M 0.31%
+360,000
New +$4.63M
GLUE icon
40
Monte Rosa Therapeutics
GLUE
$1.3B
$3.89M 0.3%
510,882
– –
KROS icon
41
Keros Therapeutics
KROS
$200M
$3.12M 0.24%
+65,000
New +$3.04M
OMIC
42
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$2.7M 0.21%
44,857
– –
WVE icon
43
Wave Life Sciences
WVE
$1.13B
$1.4M 0.11%
+200,000
New +$922K
EXAI
44
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.14M 0.09%
213,900
– –
LIAN
45
DELISTED
LianBio American Depositary Shares
LIAN
$339K 0.03%
206,415
– –
KRON
46
DELISTED
Kronos Bio
KRON
$201K 0.02%
123,839
– –
CLDX icon
47
Celldex Therapeutics
CLDX
$2.96B
– –
-165,000
Closed -$4.64M
DNTH icon
48
Dianthus Therapeutics
DNTH
$5.8B
– –
-20,000
Closed -$451K
CERE
49
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-80,000
Closed -$2.26M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Casdin Capital held 49 positions worth $1.29B, down 15% from $1.52B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Casdin Capital deployed $49.5M of net new capital in Q4 2022, opening 12 new positions and adding to 11 existing holdings. Its largest new stake was Prime Medicine: 734,350 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $60.4M trimmed.

  • Casdin Capital's largest Q4 2022 buy was Prime Medicine: 734,350 shares worth $13.6M.
  • Casdin Capital added most to Pliant Therapeutics in Q4 2022, an estimated $19.3M increase.
  • Casdin Capital's biggest Q4 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $60.4M.
  • Casdin Capital fully exited Celldex Therapeutics in Q4 2022, selling an estimated $4.64M.
  • Casdin Capital's ten largest holdings make up 65% of its $1.29B portfolio in Q4 2022.
  • Casdin Capital opened 12 new positions and closed 3 in Q4 2022.
  • Casdin Capital's portfolio value fell 15% quarter-over-quarter to $1.29B.

Based on Casdin Capital's 13F filing for Q4 2022, filed 14 Feb 2023.